About 15 results found for searched term "GSK-J2" (0.129 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M14713 | GSK-J2 | Others |
| GSK-J2 is an isomer of GSK-J1 that does not have any specific activity. GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A. | ||
| M1759 | GSK1120212 (Trametinib) | MEK |
| JTP-74057, GSK212 | ||
| Trametinib (GSK1120212; Jtp-74057) is an orally effective MEK inhibitor with IC50 of 2 nM against MEK1 and MEK2, respectively. Trametinib can activate autophagy and induce apoptosis. | ||
| M2730 | GSK-J1 | Histone demethylase |
| GSK-J1 is a potent inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A, with IC50 of 60 nM towards KDM6B. GSK J1 is selective for the H3K27 demethylases JMJD3 and UTX. | ||
| M2731 | GSK-J4 hydrochloride | Histone demethylase |
| GSK-J4 hydrochloride is a potent dual inhibitor of H3K27me3/me2-demethylases JMJD3/KDM6B and UTX/KDM6A with IC50s of 8.6 and 6.6 μM, respectively. GSK-J4 hydrochloride inhibits LPS-induced TNF-α production in human primary macrophages with an IC50 of 9 μM. GSK J4 hydrochloride is a cell permeable procompound of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM and inactive against a panel of demethylases of the JMJ family. | ||
| M2743 | GW2580 | CSF-1R (c-Fms) |
| SC-203877 | ||
| GW2580 is a selective CSF-1R inhibitor for c-FMS with IC50 of 30 nM, 150- to 500-fold selective compared to b-Raf, CDK4, c-KIT, c-SRC, EGFR, ERBB2/4, ERK2, FLT-3, GSK3, ITK, JAK2 etc. | ||
| M5149 | GSK-J4 | Histone demethylase |
| GSK-J4 is a cell permeable procompound rapidly hydrolyzed by macrophage esterases to GSK-J1, a potent selective jumonji H3K27 demethylase inhibitor. | ||
| M6855 | JW 74 | Wnt/beta-catenin |
| JW 74 is a wnt pathway inhibitor, with an IC50 of 420 nM. JW 74 targets the β-catenin destruction complex (GSK-3 beta /AXIN/APC). JW 74 increases AXIN2 and decreases active β-catenin levels in colorectal cancer (CRC) cells. | ||
| M7627 | BIO | GSK-3 |
| 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime6BIO; GSK 3 IX; GSK 3 Inhibitor IX; MLS 2052 | ||
| BIO (GSK-3 Inhibitor IX, 6-bromoindirubin-3-oxime, 6-Bromoindirubin-3'-oxime, MLS 2052) is a specific GSK-3 inhibitor, the IC50 acting on GSK-3α/β in cell-free assays is 5 nM, which is more than 16 times more selective than ACTing on CDK5. It is also a pan-JAK inhibitor with an IC50 value of 30 nM for Tyk2. BIO induces apoptosis in human melanoma cells. | ||
| M10879 | RGB-286638 | CDK |
| RGB-286638 is a potent CDK inhibitor that inhibits cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 activity,IC50 1, 2, 3, 4, 5 and 5 nM, respectively, and can inhibit GSK-3β, TAK1, Jak2 and MEK1.IC50 The values are 3, 5, 50, and 54 nM, respectively. | ||
| M13611 | RGB-286638 free base | CDK |
| RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM. | ||
| M14172 | Trametinib (DMSO solvate) | MEK |
| GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate) | ||
| Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate);JTP-74057 (DMSO solvate)) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC50s of about 2 nM. | ||
| M20836 | Indirubin-3′-oxime | GSK-3 |
| IDR3O, I3O | ||
| Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity. | ||
| M21588 | GSK2646264 | Syk |
| GSK2646264 is a potent and selective splenic tyrosine kinase (Syk) inhibitor with a pIC50 value of 7.1. GSK2646264 also inhibited other kinases, with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 for LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 penetrates into the epidermis and dermis of the skin. | ||
| M31419 | JNJ-28583113 | TRP Channel |
| JNJ-28583113 is a brain-permeable TRPM2 antagonist and blocks phosphorylation of GSK3α and β subunits by inhibiting TRPM2. In addition, JNJ-28583113 inhibits cytokine release from microglia in response to pro-inflammatory stimuli. It has the function of protecting cells from oxidative stress-induced cell death. | ||
| M56947 | GSK-J5 hydrochloride | Others |
| GSK-J5 hydrochloride is a cell-permeable ester derivative of GSK J2, inactive. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
